Sign up Australia
Proactive Investors - Run By Investors For Investors

MedMen Enterprises signs deal for cannabis dispensary in California

The company has one of only two adult-use licenses in Emeryville, California
Cannabis sign.
MedMen is a leading cannabis company in the US.

MedMen Enterprises Inc (CSE:MMEN) (OTCQB:MMNFF) announced on Wednesday it has signed an agreement to acquire a licensed dispensary from Berkeley Patients Group in Emeryville, California.

The dispensary is located in a young professional hub of the East Bay, between Oakland and Berkeley.

“California is the world’s largest legal cannabis market,” said Adam Bierman, MedMen's CEO and co-founder. “We are very proud of the footprint we’ve already established in our home state and look forward to expanding our reach to all corners of the Golden State, starting with our first store in Northern California.”

As a result of the transaction, MedMen will have one of only two adult-use licenses issued in Emeryville, just outside of San Francisco.

READ: Nevada declares ‘MedMen Day’ as cannabis company continues its expansion

Shares of MedMen closed in New York on Tuesday up 1.1% at $4.52. In Canada, the stock climbed 5.8% to finish on Tuesday at C$5.83.

MedMen is based in Los Angeles and operates eight dispensaries in southern California. The new store is expected to open in 2019.

The company will pay a combination of cash at closing and shares of MedMen in an undisclosed amount. The transaction is expected to close within 90 days of signing.

Emeryville is home to the national headquarters of corporations such as Pixar Animation Studios, Peet’s Coffee & Tea, Jamba Juice and Cliff Bar. 

MedMen is a leading cannabis company in the US. MedMen brings expertise and capital to the cannabis industry and is one of the nation’s largest financial supporters of progressive marijuana laws.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full MMEN profile View Profile

MedMen Enterprises Inc Timeline

Related Articles

Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
scientist in lab
August 31 2018
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use